LHDX - Lucira COVID-19 test kit identifies viral variants shares up 14%

Lucira Health (LHDX) shares surge 14% premarket on news that its Lucira molecular test kit can successfully identify the “double mutant” variant of COVID-19. The “double mutant” variant was first identified in India on March 24, and found in California on March 25. Unlike other variants, it has two genetic mutation sequences that the Center for Disease Control ((CDC)) is tracking. “... Lucira test kit has been reactive to more than 99.9% of available COVID-19 viral sequences, which are roughly 30,000 letters long," said Dr. Debkishore Mitra,  Chief Technology Officer and co-founder. Lucira’s 'swab, stir and detect’ test platform demonstrated that 100% of users successfully performed the test in less than about two minutes of hands-on time. The current centralized laboratory testing environment takes two to 14 days to generate similarly accurate test results.

For further details see:

Lucira COVID-19 test kit identifies viral variants, shares up 14%